288 related articles for article (PubMed ID: 18820850)
21. Osteonecrosis of the jaw: dental outcomes in metastatic breast cancer patients treated with bisphosphonates with/without bevacizumab.
Ngamphaiboon N; Frustino JL; Kossoff EB; Sullivan MA; O'Connor TL
Clin Breast Cancer; 2011 Aug; 11(4):252-7. PubMed ID: 21729657
[TBL] [Abstract][Full Text] [Related]
22. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis.
Rizzoli R; Burlet N; Cahall D; Delmas PD; Eriksen EF; Felsenberg D; Grbic J; Jontell M; Landesberg R; Laslop A; Wollenhaupt M; Papapoulos S; Sezer O; Sprafka M; Reginster JY
Bone; 2008 May; 42(5):841-7. PubMed ID: 18314405
[TBL] [Abstract][Full Text] [Related]
23. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
Bamias A; Kastritis E; Bamia C; Moulopoulos LA; Melakopoulos I; Bozas G; Koutsoukou V; Gika D; Anagnostopoulos A; Papadimitriou C; Terpos E; Dimopoulos MA
J Clin Oncol; 2005 Dec; 23(34):8580-7. PubMed ID: 16314620
[TBL] [Abstract][Full Text] [Related]
24. Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology.
Fusco V; Santini D; Armento G; Tonini G; Campisi G
Expert Opin Drug Saf; 2016 Jul; 15(7):925-35. PubMed ID: 27074901
[TBL] [Abstract][Full Text] [Related]
25. Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw: Is there a diverse relationship of amino- and non-aminobisphosphonates?
Diel IJ; Fogelman I; Al-Nawas B; Hoffmeister B; Migliorati C; Gligorov J; Väänänen K; Pylkkänen L; Pecherstorfer M; Aapro MS
Crit Rev Oncol Hematol; 2007 Dec; 64(3):198-207. PubMed ID: 17855108
[TBL] [Abstract][Full Text] [Related]
26. [Osteonecrosis of the jaws by long term therapy with bisphosphonates].
Piesold JU; Al-Nawas B; Grötz KA
Mund Kiefer Gesichtschir; 2006 Sep; 10(5):287-300. PubMed ID: 16960697
[TBL] [Abstract][Full Text] [Related]
27. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research.
Khosla S; Burr D; Cauley J; Dempster DW; Ebeling PR; Felsenberg D; Gagel RF; Gilsanz V; Guise T; Koka S; McCauley LK; McGowan J; McKee MD; Mohla S; Pendrys DG; Raisz LG; Ruggiero SL; Shafer DM; Shum L; Silverman SL; Van Poznak CH; Watts N; Woo SB; Shane E;
J Bone Miner Res; 2007 Oct; 22(10):1479-91. PubMed ID: 17663640
[TBL] [Abstract][Full Text] [Related]
28. Disease-specific risk for an osteonecrosis of the jaw under bisphosphonate therapy.
Jung TI; Hoffmann F; Glaeske G; Felsenberg D
J Cancer Res Clin Oncol; 2010 Mar; 136(3):363-70. PubMed ID: 19701651
[TBL] [Abstract][Full Text] [Related]
29. Bisphosphonate-associated osteonecrosis of the jaw in breast cancer patients: recommendations for prevention and treatment.
Fehm T; Felsenberg D; Krimmel M; Solomayer E; Wallwiener D; Hadjii P
Breast; 2009 Aug; 18(4):213-7. PubMed ID: 19651512
[TBL] [Abstract][Full Text] [Related]
30. [Osteonecrosis of the jaw associated with the use of bisphosphonates in multiple myeloma: report of four cases and literature review].
Li LH; Wu XB; Chen WM; Chen JX; Wu Y; Chen SL
Zhonghua Yi Xue Za Zhi; 2008 Nov; 88(42):2986-7. PubMed ID: 19080077
[TBL] [Abstract][Full Text] [Related]
31. [Osteonecrosis of the jaw].
Drozdzowska B
Endokrynol Pol; 2011; 62 Suppl 3():4-9. PubMed ID: 22161980
[TBL] [Abstract][Full Text] [Related]
32. Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome.
Van den Wyngaert T; Claeys T; Huizing MT; Vermorken JB; Fossion E
Ann Oncol; 2009 Feb; 20(2):331-6. PubMed ID: 18953067
[TBL] [Abstract][Full Text] [Related]
33. Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies.
Fehm T; Beck V; Banys M; Lipp HP; Hairass M; Reinert S; Solomayer EF; Wallwiener D; Krimmel M
Gynecol Oncol; 2009 Mar; 112(3):605-9. PubMed ID: 19136147
[TBL] [Abstract][Full Text] [Related]
34. Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients.
Walter C; Al-Nawas B; du Bois A; Buch L; Harter P; Grötz KA
Cancer; 2009 Apr; 115(8):1631-7. PubMed ID: 19156913
[TBL] [Abstract][Full Text] [Related]
35. Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients.
Pozzi S; Marcheselli R; Sacchi S; Baldini L; Angrilli F; Pennese E; Quarta G; Stelitano C; Caparotti G; Luminari S; Musto P; Natale D; Broglia C; Cuoghi A; Dini D; Di Tonno P; Leonardi G; Pianezze G; Pitini V; Polimeno G; Ponchio L; Masini L; Musso M; Spriano M; Pollastri G;
Leuk Lymphoma; 2007 Jan; 48(1):56-64. PubMed ID: 17325848
[TBL] [Abstract][Full Text] [Related]
36. Osteonecrosis of the jaw.
Watts NB; Marciani RD
South Med J; 2008 Feb; 101(2):160-5. PubMed ID: 18364618
[TBL] [Abstract][Full Text] [Related]
37. Bisphosphonate-associated osteonecrosis of the jaw: conclusions based on an analysis of case series.
Landesberg R; Wilson T; Grbic JT
Dent Today; 2006 Aug; 25(8):52, 54-7. PubMed ID: 16925161
[TBL] [Abstract][Full Text] [Related]
38. Osteonecrosis of the jaw and the role of bisphosphonates: a critical review.
Silverman SL; Landesberg R
Am J Med; 2009 Feb; 122(2 Suppl):S33-45. PubMed ID: 19187811
[TBL] [Abstract][Full Text] [Related]
39. Bisphosphonate-associated osteonecrosis of the jaw: a key role of inflammation?
Lesclous P; Abi Najm S; Carrel JP; Baroukh B; Lombardi T; Willi JP; Rizzoli R; Saffar JL; Samson J
Bone; 2009 Nov; 45(5):843-52. PubMed ID: 19631301
[TBL] [Abstract][Full Text] [Related]
40. Osteonecrosis of the jaw correlated to bisphosphonate therapy in non-oncologic patients: clinicopathological features of 24 patients.
Favia G; Pilolli GP; Maiorano E
J Rheumatol; 2009 Dec; 36(12):2780-7. PubMed ID: 19884275
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
